Study details
Enrolling now
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Medical University of South Carolina
NCT IDNCT04061746ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 7.1 years
Ages
18–40
Locations
1 site in SC
What this study is about
This trial is testing the safety and effectiveness of a treatment using mesenchymal stem cells (MSCs) to help people with type 1 diabetes. The treatment involves infusing MSCs into participants, comparing it to a placebo infusion.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Mesenchymal Stem Cells (MSCs)
- 2.Receive Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
Immunological Agents
Body systems
Endocrinology